Abstract

One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.

Keywords

CTLA-4ImmunogenicityBlockadeCD28ImmunologyImmunityRegulatorImmune systemAntibodyCancer researchT cellBiologyMedicineReceptorInternal medicine

Affiliated Institutions

Related Publications

Immune Therapy for Cancer

Michael Dougan , Glenn Dranoff

Over the past decade, immune therapy has become a standard treatment for a variety of cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses ar...

2008 Annual Review of Immunology 611 citations

Immune Regulation of Cancer

Mary L. Disis

Innate and adaptive immune system cells play a major role in regulating the growth of cancer. Although it is commonly thought that an immune response localized to the tumor will...

2010 Journal of Clinical Oncology 480 citations

Publication Info

Year
1996
Type
article
Volume
271
Issue
5256
Pages
1734-1736
Citations
3810
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3810
OpenAlex

Cite This

Dana R. Leach, Matthew F. Krummel, James P. Allison (1996). Enhancement of Antitumor Immunity by CTLA-4 Blockade. Science , 271 (5256) , 1734-1736. https://doi.org/10.1126/science.271.5256.1734

Identifiers

DOI
10.1126/science.271.5256.1734